Status:
COMPLETED
Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of AZD2066 when given as multiple doses to Japanese healthy male subjects. Four (4) consecutive multiple-ascen...
Detailed Description
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of AZD2066 when given as multiple doses to Japanese healthy male subjects. Four (4) consecutive multiple-ascen...
Eligibility Criteria
Inclusion
- Provision of signed informed consent
- Healthy Japanese males as judged by the investigator
- Clinically normal physical findings and laboratory values as judged by the investigator and a normal resting ECG.
Exclusion
- History of somatic disease/condition, which may interfere with the objectives of the study, as judged by the investigator.
- History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder.
- Intake of medicine (except occasional paracetamol) within first 2 weeks before first administration of study drug.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT00766012
Start Date
September 1 2008
End Date
July 1 2009
Last Update
August 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research SIte
Fukuoka, Japan